Solarplast (R) Supplementation Effects Following High-intensity Resistance Exercise

NCT06432868 | Recruiting

• 1 other identifier: 927
• Study Type: interventional
• Target: 46
• Locations: 1 country
• Sites: 1

Brief Summary

The primary goal of this investigation is to assess whether Solarplast (R) supplementation will improve recovery following heavy resistance exercise in active adults. The primary questions to be addressed are: Does Solarplast (R) decrease muscle damage and inflammation associated with heavy resistance exercise? Does Solarplast (R) reduce the decline in performance associate with heavy resistance exercise? Researchers will compare Solarplast (R) to a placebo (a look-alike substance that contains no active ingredients) to see if Solarplast (R) is effective at improving recovery. Participants will be asked to: Take Solarplast (R) or placebo daily for 4 weeks Visit the laboratory at least once per week to receive their supplement Report to the lab for 3 consecutive visits following supplementation to complete a heavy resistance training session and follow-up testing.

Conditions

Muscle Damage

Outcome Measures

Primary Outcomes (1)

• Creatine Kinase Activity

  Marker of Muscle Damage

  Acute changes following exercise for 48 hours

Secondary Outcomes (7)

• Myoglobin Concentration

  Acute changes following exercise for 24 hours

• Vertical Jump Height

  Acute changes following exercise for 48 hours

• Mean Squat Velocity

  Acute changes following exercise for 48 hours

• Peak Isometric Muscle Force

  Acute changes following exercise for 48 hours

• Rate of Force Development

  Acute changes following exercise for 48 hours

Other Outcomes (18)

• Rate of Muscular Fatigue

  Acute changes following exercise for 48 hours

• Rate of Muscular Fatigue

  Change in Resting Values over 4 weeks of supplementation

• Lactate Dehydrogenase Activity

  Acute changes following exercise for 48 hours

Study Arms (2)

Solarplast (R)

ACTIVE COMPARATOR

100mg/day of Solarplast (R) supplementation (28 days).

Dietary Supplement: Solarplast (R)

Placebo

PLACEBO COMPARATOR

100mg/day of Placebo (maltodextrin (98.8%) and medium chain triglycerides (1.2%)).

Dietary Supplement: Placebo

Interventions

Solarplast (R) DIETARY_SUPPLEMENT

Daily supplementation for 28 days prior to heavy resistance exercise.

Solarplast (R)

Placebo DIETARY_SUPPLEMENT

Daily supplementation for 28 days prior to heavy resistance exercise.

Placebo

Eligibility Criteria

• Age: 18 Years - 35 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Recreationally-active (participated in at least 2 weight training workouts per week over the previous year) and participates in at least 3h of total structured exercise/week as determined by the health and activity questionnaire.
• Subject is judged by the Investigator to be healthy and free of any physical limitations (determined by health and activity questionnaire)
• Subject has a body mass index of 18.0-34.9 kg/m2, inclusive
• Subject is willing to maintain habitual diet throughout the study period
• Subject is willing to abstain from dietary supplementation throughout the duration of the study.
• Subject understands the study procedures and signs forms providing informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigators

You may not qualify if:

• Subject is currently or will be enrolled in another clinical trial.
• Subject is a habitual consumer of tea/antioxidants defined as \> 8 oz/day of either green or black tea within the 14 days prior to the screening visit.
• Subject has a history or presence of a clinically relevant cardiac, renal, hepatic, endocrine (including diabetes mellitus), pulmonary, biliary, gastrointestinal, pancreatic, or neurologic disorder.
• Subject has a history or presence of cancer in the prior 2 years, except for non-melanoma skin cancer.
• Subject is unable to perform physical exercise (determined by health and activity questionnaire)
• Subject is engaged in an extreme diet including but not limited to, Atkins, South Beach, Intermittent Fasting, etc.
• Subject is allergic to the study product or placebo
• Subject is taking any other nutritional supplement or performance enhancing drug (determined from health and activity questionnaire)
• Subject has any chronic illness that causes continuous medical care
• Taking any type of prescription or over-the-counter medication including but not limited to corticosteroids, non-steroidal anti-inflammatory drugs, and antibiotics within the 14 days prior to the screening visit.

Sponsors & Collaborators

• Kent State University: lead

Study Sites (1)

Kent State University - Exercise Science & Exercise Physiology

Kent, Ohio, 44242, United States

RECRUITING

Central Study Contacts

Adam R Jajtner, PhD

CONTACT

330-672-0212; ajajtner@kent.edu

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor

Study Record Dates

• First Submitted: April 29, 2024
• First Posted: May 29, 2024
• Study Start: April 17, 2024
• Primary Completion: March 31, 2025
• Study Completion: March 31, 2025
• Last Updated: May 29, 2024

Record last verified: 2024-05

Locations

US (1)